Borkowetz A, Froehner M, Rauner M, et al. - Using a tissue microarray with prostate tissue specimens from 400 prostate cancer (PCa) patients who underwent radical prostatectomy, researchers focused on the link of immunohistochemical neuropilin-2 (NRP2; a member of the neuropilin receptor family) expression with clinicopathological data in patients with PCa. The patients having high-risk factors such as extraprostatic extension, Gleason Score ≥ 8 and/or the presence of regional lymph node metastases (pN1) were especially given attention. In correlation with patients' outcome, the evaluation of protein levels of NRP2, the vascular endothelial growth factor C and oncogenic v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) gene as an indicator for TMPRSS2-ERG fusion was done. They identified a significant link of NRP2 immunostaining with shorter cancer-specific survival (CSS) in ERG-negative tumors. In ERG-positive tumors, NRP2 expression had no prognostic influence on CSS. Among participants, particularly in those with a high-risk PCa and those with ERG-negative PCa, the importance of NRP2 as a prognostic marker for a worse clinical outcome was evident in this study.